EA6141
OPEN TO ACCRUAL
PII/III Study of Nivo+ Ipi + Sargramostim vs. Nivo + Ipi in Pts w/ Stage III/IV Melanoma
NRGHN014
OPEN TO ACCRUAL
P3 Neoadjuvant Immunotherapy w/Response-Adapted Tx vs SOC for Resectable Stage III/IV Cutaneous SCC
UW18132
OPEN TO ACCRUAL
Evaluation of Circulating Tumor Cells in Melanoma
UW21049
OPEN TO ACCRUAL
PII Hypofractionated VS conventional fractionated RT in soft tissue sarcomas
UW22119
OPEN TO ACCRUAL
Phase I/IIa theranostic study using 212Pb in metastatic melanoma
UW23071
OPEN TO ACCRUAL
AU-011-301
UW23077
OPEN TO ACCRUAL
Correlating Early FDG PET/CT and ctDNA in ICI-Treated Melanoma Patients
UW24061
OPEN TO ACCRUAL
Ph 3 Study w/Combo of Fianlimab+Cemiplimab vs Relatlimab+Nivo in Participants w/Metastatic Melanoma
UW24072
OPEN TO ACCRUAL
Phase 1 IFx-Hu2.0 + Pembrolizumab in Advanced or Metastatic Merkel Cell Carcinoma
UW24110
OPEN TO ACCRUAL
Ph2/3 Open-label RP2 w/ Nivolumab vs Ipilimumab w/ Nivolumab in pts w Mets Uveal Melanoma